86/100
High Financial Strength
18/100
Expensive Valuation
38/100
Technically Neutral
Strength
7
Weakness
4
Opportunity
1
Threats
0
Market Cap (Cr)
PE Ratio
Price to Book Ratio
RSI
Net Profit Margin
Announcement under Regulation 30 (LODR)-Change in Directorate
Disclosure attached
Closure of Trading Window
Intimation of Closure of Trading Window
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meeting(s)
Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisements published on September 12 2024
Intimation Of NCLT Order Sanctioning The Scheme Of Amalgamation Between Two Subsidiary Companies Of
Honble NCLT Allahabad Bench sanctioned the Scheme of Amalgamation between two Subsidiary Companies of Dr. Lal PathLabs Limited
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meetings
Board Meeting Outcome for Outcome Of Board Meeting Dated Aug 13 2024
Outcome of Board Meeting dated Aug 13 2024
Grant Of Stock Options
Grant of Stock Option
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Earnings Call Transcript for Q1 FY25
Change In Designation Of Mr. Ved Prakash Goel
Mr. Ved Prakash Goel Group Chief Financial Officer (KMP) has been re-designated as Group Chief Financial Officer and Chief Executive Officer - International Business (KMP) with effect from August 13 2024
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of ESOPs
Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Newspaper Publication
Results For Quarter Ended June 30 2024
Results for quarter ended June 30 2024
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on unaudited financial results for quarter ended June 30 2024
Announcement under Regulation 30 (LODR)-Investor Presentation
Earnings presentations on unaudited financial results for quarter ended June 30 2024
Re-Appointment Of M/S Chandrasekaran Associates Company Secretaries As The Secretarial Auditors Of T
As attached
Announcement under Regulation 30 (LODR)-Dividend Updates
As attached
Grant Of Esops Under CompanyS ESOP Plan 2022
As attached
Board Meeting Outcome for Outcome Of Board Meeting Held On August 07 2024
Outcome of Board Meeting held on August 07 2024
Record Date For Interim Dividend For FY 2024-25
As attached
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meeting
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recording of Earnings Conference Call with Investors/ Analysts for Q1 FY25
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find attached the invite of the Conference Call for Investors/ Analysts to be held on Wednesday August 7 2024 at 5:30 P.M. (IST) to discuss the financial and... More>
Board Meeting Intimation for Approval Of Un-Audited (Standalone & Consolidated) Financial Results Of
Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2024 inter alia to consider and approve Un-audited (Standalone & Consolidated) Financial Results of the Company for the Quarter ended June 30 2024 and... More>
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Certificate attached
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of the 30th AGM is attached
Shareholder Meeting / Postal Ballot-Scrutinizers Report
Disclosure is attached
Closure of Trading Window
Intimation of Closure of Trading Window
Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication is Attached
Business Responsibility and Sustainability Reporting (BRSR)
BRSR for FY 2023-24 attached
Notice Convening The 30Th Annual General Meeting
Notice convening the 30th Annual General Meeting attached
Reg. 34 (1) Annual Report.
Annual Report for FY 2023-24 attached
Announcement under Regulation 30 (LODR)-Newspaper Publication
Disclosure attached
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meeting
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Disclosure attached
Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for Q4 & FY 24 attached
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meetings
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Q4 & F.Y. 2024 Earnings Call Transcript is attached
Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication attached
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Disclosure Attached
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of ESOP
Grant Of ESOP
Attached
Announcement under Regulation 30 (LODR)-Investor Presentation
Earnings presentation on Audited Financial Results (Standalone & Consolidated) for Q4 and FY ended March 31 2024
Re-Appointment Of Cost Auditors And Internal Auditors
Attached
Announcement under Regulation 30 (LODR)-Investor Presentation
Revised Earnings presentation on Audited financial results for Q4 and financial year ended March 31 2024
Record Date For Final Dividend
Attached
Re-Appointment Of Dr. Vandana Lal
Attached
Announcement under Regulation 30 (LODR)-Dividend Updates
Attached
Results For Q4 And FY Ended March 31 2024
Attached
Board Meeting Outcome for Outcome Of Board Meeting
Outcome of Board Meeting
AGM To Be Held On June 29 2024
Attached
Record Date For Final Dividend
Attached
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith Press Release on Audited Financial Results (Standalone & Consolidated) for Q4 and FY ended March 31 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find attached the invite of the Conference Call for Investors/ Analysts to be held on Friday May 10 2024 at 03.30 P.M. (IST) to discuss the financial and... More>
Compliances-Reg.24(A)-Annual Secretarial Compliance
Certificate attached for financial year ended March 31 2024
Board Meeting Intimation for Consideration And Approval Of The Audited (Standalone & Consolidated) F
Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/05/2024 inter alia to consider and approve the Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Financial year... More>
Update On Resignation Of Mr. Bharath U Chief Executive Officer (Key Managerial Personnel)
Disclosure on update on Resignation of Mr. Bharath U is attached
Announcement under Regulation 30 (LODR)-Newspaper Publication
Disclosure under Regulation 30- Newspaper Publication
Compliance Under Regulation 40(10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulat
Disclosure attached
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Disclosure Attached
Compliance Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulatio
Disclosure attached
Received Assessment Order Issued By Income Tax Department
Received Assessment Order issued by Income Tax Department
Closure of Trading Window
Intimation of Closure of Trading Window
Received An Assessment Order And Demand Notice Issued By Income Tax Department
Disclosure attached under Regulation 30 of SEBI (LODR) 2015
Received An Assessment Order And Demand Notice Issued By Income Tax Department
Disclosure attached under Regulation 30 of SEBI (LODR) 2015
Appointment Of Chief Executive Officer (Key Managerial Personnel)
Appointment of Chief Executive Officer (KMP)
Change In Authorized Persons For The Purpose Of Determining Materiality Of Any Event Or Information
Change in authorized persons for the purpose of determining materiality of any event or information which shall be effective from May 21 2024
Board Meeting Outcome for Appointment Of Chief Executive Officer (Key Managerial Personnel)
Based on recommendations of Nomination & Remuneration Committee the Board of Directors in their meeting held today i.e. March 17 2024 inter-alia approved the re-designation of Mr. Shankha Banerjee by appointing him as Chief Executive Officer (CEO) and Key Managerial... More>
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meeting
Announcement under Regulation 30 (LODR)-Resignation of Chief Executive Officer (CEO)
Resignation of Chief Executive Officer (CEO)
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meeting
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meeting
Announcement under Regulation 30 (LODR)-Credit Rating
CARE Ratings Limited vide its letter dated February 14 2024 re-affirmed the Credit Rating for the bank facilities of the Company.
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of conference call on Financial Results for Q3 & 9M FY 24
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meetings
Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication of financial results for Quarter and Nine Months ended December 31 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 and 46(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please note that the audio recording of the Companys Earnings Conference Call dated February 01 2024 with Investors/ Analysts for Q3 & 9M FY24 is... More>
Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation on Q3 & 9M FY 24 Financial Results
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on un-audited Financial Results for the Quarter and Nine Months ended December 31 2023
Board Of Directors In Their Meeting Held On February 01 2024 Approved Payment Of 2Nd Interim Dividen
Board of Directors in their meeting held on February 01 2024 approved payment of 2nd Interim Dividend for FY 2023-24
Corporate Action-Board approves Dividend
Board of Directors in their meeting held on February 01 2024 approved payment of 2nd Interim Dividend for FY 2023-24
Announcement under Regulation 30 (LODR)-Dividend Updates
Board of Directors in their meeting held on February 01 2024 inter-alia approved payment of 2nd Interim Dividend for FY 2023-24
Board Meeting Outcome for Outcome Of Board Meeting Dated February 01 2024
Outcome of Board Meeting held on February 01 2024
Financial Results For The Quarter And Nine Months Ended December 31 2023
Financial Results for the quarter and nine months ended December 31 2023
Closure of Trading Window
In continuation to our letter dated December 26 2023 and in line with the provisions of the SEBI (PIT) Regulation 2015 and companys code for prevention of insider trading the trading window for dealing in securities of the company is closed and shall re-open after 48... More>
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find attached the invite of the Conference Call for Investors/Analysts to be held on Thursday February 01 2024 at 5:00 P.M. (IST) to discuss the financial... More>
Board Meeting Intimation for Approval Of The Un-Audited (Standalone & Consolidated) Financial Result
Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/02/2024 inter alia to consider and approve the Un-audited (Standalone & Consolidated) Financial Results for the Quarter and Nine Months ended December 31... More>
